Publicaciones
PDF

Poster-1_-Eprecis_Achard_2017_EBF-2017.pdf

Summary

Good syringeability is important to facilitate the use of injectable products in the field and to ensure compliance. Eprecis® 2% ” (Ceva, Eprinomectin 20 mg/mL) has demonstrated a significant better syringeability than the other two products tested with the two different needles tested. The superior performance can be explained by the active ingredient and the different excipients used in their formulation. This high fluidity strongly increases the comfort and convenience of use in the field.

:

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.